Show simple item record

Human endotoxin administration as an experimental model in drug development.

dc.contributor.author Noveck, Robert
dc.contributor.author Suffredini, AF
dc.coverage.spatial United States
dc.date.accessioned 2015-12-15T16:20:16Z
dc.date.issued 2014-10
dc.identifier http://www.ncbi.nlm.nih.gov/pubmed/25236665
dc.identifier clpt2014146
dc.identifier.uri http://hdl.handle.net/10161/11171
dc.description.abstract Linking human physiology to inflammatory mechanisms discovered in vitro or in animal models is essential to determine their importance. Innate immunity underlies many of these inflammatory responses in health and disease. Bacterial endotoxin is the quintessential trigger of innate immune responses. When administered to humans, endotoxin has been an important means of demonstrating key inflammatory mechanisms in vivo. Furthermore, endotoxin challenges have provided opportunities to test the effects of novel inflammation-modifying agents in humans.
dc.language eng
dc.relation.ispartof Clin Pharmacol Ther
dc.relation.isversionof 10.1038/clpt.2014.146
dc.subject Anti-Inflammatory Agents
dc.subject Drug Discovery
dc.subject Endotoxins
dc.subject Humans
dc.subject Infection
dc.subject Inflammation
dc.title Human endotoxin administration as an experimental model in drug development.
dc.type Journal article
pubs.author-url http://www.ncbi.nlm.nih.gov/pubmed/25236665
pubs.begin-page 418
pubs.end-page 422
pubs.issue 4
pubs.organisational-group Duke
pubs.organisational-group Staff
pubs.publication-status Published
pubs.volume 96
dc.identifier.eissn 1532-6535


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record